{"since":"2026-08-07","new_medicines":[],"label_updates":[{"medicine":"Zanubrutinib","brand":"Brukinsa","updated":"2026-11-04"},{"medicine":"Entrectinib","brand":"Rozlytrek","updated":"2026-11-03"},{"medicine":"Pembrolizumab","brand":"Keytruda","updated":"2026-10-30"},{"medicine":"Ciltacabtagene autoleucel","brand":"Carvykti","updated":"2026-10-29"},{"medicine":"Dinutuximab beta","brand":"Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)","updated":"2026-10-29"},{"medicine":"Nivolumab","brand":"Opdivo","updated":"2026-10-29"},{"medicine":"Avapritinib","brand":"Ayvakyt","updated":"2026-10-29"},{"medicine":"Imatinib","brand":"Glivec","updated":"2026-10-27"},{"medicine":"Sugemalimab","brand":"Cejemly","updated":"2026-10-22"},{"medicine":"Trastuzumab deruxtecan","brand":"Enhertu","updated":"2026-10-20"},{"medicine":"Polatuzumab vedotin","brand":"Polivy","updated":"2026-10-20"},{"medicine":"Mogamulizumab","brand":"Poteligeo","updated":"2026-10-20"},{"medicine":"Glofitamab","brand":"Columvi","updated":"2026-10-20"},{"medicine":"Enfortumab vedotin","brand":"Padcev","updated":"2026-10-16"},{"medicine":"Cabozantinib","brand":"Cabometyx","updated":"2026-10-15"},{"medicine":"Selumetinib","brand":"Koselugo","updated":"2026-10-15"},{"medicine":"Belzutifan","brand":"Welireg","updated":"2026-10-14"},{"medicine":"Cabozantinib","brand":"Cometriq","updated":"2026-10-13"},{"medicine":"Dostarlimab","brand":"Jemperli","updated":"2026-10-13"},{"medicine":"Lazertinib","brand":"Lazcluze","updated":"2026-10-12"},{"medicine":"Serplulimab","brand":"Hetronifly","updated":"2026-10-08"},{"medicine":"Tepotinib","brand":"Tepmetko","updated":"2026-10-08"},{"medicine":"Sotorasib","brand":"Lumykras","updated":"2026-10-08"},{"medicine":"Ibrutinib","brand":"Imbruvica","updated":"2026-10-07"},{"medicine":"Mosunetuzumab","brand":"Lunsumio","updated":"2026-10-07"},{"medicine":"Acalabrutinib","brand":"Calquence","updated":"2026-10-07"},{"medicine":"Relugolix","brand":"Orgovyx","updated":"2026-10-02"},{"medicine":"Odronextamab","brand":"Ordspono","updated":"2026-10-02"},{"medicine":"Dasatinib","brand":"Sprycel","updated":"2026-10-02"},{"medicine":"Tabelecleucel","brand":"Ebvallo","updated":"2026-10-02"}],"entry_changes":[{"date":"2026-10-31","medicine":"Pembrolizumab (Keytruda)","added":[],"changed":["Melanoma, no biomarker required, Advanced, Monotherapy: Eligibility","Urothelial, no biomarker required, Neoadjuvant, early, + enfortumab vedotin: Eligibility","Urothelial, no biomarker required, Adjuvant, early, + enfortumab vedotin: Eligibility","TNBC, no biomarker required, Adjuvant, Monotherapy: Prior therapy, Eligibility","Ovarian, PD-L1 CPS ≥ 1, 2nd line, advanced, + paclitaxel, with or without bevacizumab: Stage, Requirement, Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Abiraterone (Abiraterone Krka)","added":[],"changed":["Prostate, no biomarker required, 1st line, metastatic, + prednisone or prednisolone: Tumour, Line, Prior therapy, Eligibility","Prostate, no biomarker required, 2nd line, metastatic, + prednisone or prednisolone: Tumour, Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Brentuximab vedotin (Adcetris)","added":[],"changed":["Hodgkin, CD30 CD30+, 3rd line+, Monotherapy: Requirement, Cut-off, Prior therapy, Eligibility","T-cell lymphoma, no biomarker required, 2nd line, Monotherapy: Prior therapy"],"removed":[]},{"date":"2026-10-26","medicine":"Everolimus (Afinitor)","added":[],"changed":["NET, no biomarker required, Advanced, Monotherapy: Tumour, Eligibility, review_fields"],"removed":[]},{"date":"2026-10-26","medicine":"Niraparib + abiraterone (Akeega)","added":[],"changed":["Prostate, germline and/or somatic BRCA 1/2 mutations, 1st line, metastatic, + prednisone or prednisolone: Line, Requirement, Cut-off, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Nogapendekin alfa inbakicept (Anktiva)","added":["Urothelial, no biomarker required, Early, + Bacillus Calmette-Guérin (BCG)"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Obecabtagene autoleucel (Aucatzyl)","added":[],"changed":["ALL, no biomarker required, 2nd line, Monotherapy: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Repotrectinib (Augtyro)","added":[],"changed":["Tumour-agnostic, NTRK fusion, Advanced, Monotherapy: Cut-off, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Bevacizumab (Avastin)","added":[],"changed":["Breast, no biomarker required, 1st line, metastatic, + capecitabine: Prior therapy, Eligibility, review_fields","Ovarian, no biomarker required, 2nd line, advanced, + carboplatin and gemcitabine or carboplatin and paclitaxel: Prior therapy"],"removed":[]},{"date":"2026-10-26","medicine":"Avapritinib (Ayvakyt)","added":[],"changed":["Mastocytosis, no biomarker required, Any line, Monotherapy: Prior therapy"],"removed":[]},{"date":"2026-10-26","medicine":"Avelumab (Bavencio)","added":[],"changed":["Urothelial, no biomarker required, Maintenance, advanced, Monotherapy: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Tasonermin (Beromun)","added":["Sarcoma, no biomarker required, Advanced, + melphalan via mild hyperthermic isolated limb perfusion (ILP)"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Inotuzumab ozogamicin (Besponsa)","added":[],"changed":["ALL, CD22-positive, 2nd line, Monotherapy: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Ropeginterferon alfa-2b (Besremi)","added":["MPN, no biomarker required, Any line, Monotherapy"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Belantamab mafodotin (Blenrep)","added":[],"changed":["Myeloma, no biomarker required, 2nd line, + bortezomib and dexamethasone: Prior therapy, Eligibility","Myeloma, no biomarker required, 2nd line, + pomalidomide and dexamethasone: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Blinatumomab (Blincyto)","added":[],"changed":["ALL, CD19-positive, Philadelphia chromosome-negative, 2nd line, Monotherapy: Requirement, Cut-off, Prior therapy","ALL, CD19-positive, Philadelphia chromosome-negative, 2nd line, Monotherapy: Requirement, Cut-off, Prior therapy, Eligibility","ALL, CD19-positive, Philadelphia chromosome-negative, Consolidation, Monotherapy: Requirement, Cut-off, Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Bosutinib (Bosulif)","added":[],"changed":["CML, Philadelphia chromosome / BCR::ABL1 translocation, 1st line, Monotherapy: Tumour, Requirement, Cut-off, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Lisocabtagene maraleucel (Breyanzi)","added":[],"changed":["LBCL/DLBCL, no biomarker required, 2nd line, Monotherapy: Tumour, Prior therapy, Eligibility","LBCL/DLBCL, no biomarker required, 2nd line, Monotherapy: Tumour, Prior therapy, Eligibility","LBCL/DLBCL, no biomarker required, 2nd line, Monotherapy: Tumour, Prior therapy, Eligibility","FL, no biomarker required, 2nd line, Monotherapy: Tumour, Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Cabozantinib (Cabometyx)","added":[],"changed":["NET, no biomarker required, 2nd line, advanced, Monotherapy: Tumour, Site, Prior therapy","NET, no biomarker required, 2nd line, advanced, Monotherapy: Tumour, Site, Prior therapy"],"removed":[]},{"date":"2026-10-26","medicine":"Leuprorelin (Camcevi)","added":["Prostate, no biomarker required, Advanced, Monotherapy","Prostate, no biomarker required, Any line, + radiotherapy"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Ciltacabtagene autoleucel (Carvykti)","added":[],"changed":["Myeloma, no biomarker required, 2nd line, Monotherapy: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Sugemalimab (Cejemly)","added":[],"changed":["NSCLC, PD-L1 expression ≥ 1%, EGFR/ALK/ROS1-negative, Consolidation, locally advanced, Monotherapy: Requirement, Cut-off, Eligibility, review_fields"],"removed":[]},{"date":"2026-10-26","medicine":"Ramucirumab (Cyramza)","added":[],"changed":["CRC, no biomarker required, 2nd line, metastatic, + FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil): Regimen, Prior therapy"],"removed":[]},{"date":"2026-10-26","medicine":"Dasatinib (Dasatinib Accord Healthcare)","added":[],"changed":["CML, BCR::ABL1 fusion, 2nd line, Monotherapy: Prior therapy, Eligibility, review_fields"],"removed":[]},{"date":"2026-10-26","medicine":"Datopotamab deruxtecan (Datroway)","added":[],"changed":["TNBC, triple-negative (ER-negative, PR-negative, HER2-negative), 1st line, advanced, Monotherapy: Biomarker, Alteration, Requirement, Cut-off, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Tabelecleucel (Ebvallo)","added":["PTLD, EBV-positive, 2nd line, Monotherapy"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Elranatamab (Elrexfio)","added":["Myeloma, no biomarker required, 3rd line+, Monotherapy"],"changed":[],"removed":[]},{"date":"2026-10-26","medicine":"Elotuzumab (Empliciti)","added":[],"changed":["Myeloma, no biomarker required, 3rd line+, + pomalidomide and dexamethasone: Prior therapy, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Vismodegib (Erivedge)","added":["BCC, no biomarker required, Metastatic, Monotherapy"],"changed":["BCC, no biomarker required, Locally advanced, Monotherapy: Stage, Eligibility"],"removed":[]},{"date":"2026-10-26","medicine":"Apalutamide (Erleada)","added":[],"changed":["Prostate, no biomarker required, Metastatic, + androgen deprivation therapy (ADT): Eligibility"],"removed":[]}],"dataset":{"version":"52f637a50d","ema_data_of":"2026-11-05","checked":"2026-11-05","notice":"EU label indications from EMA product information (SmPC section 4.1), generated by AI and not reviewed by a person. A non-commercial reference for education and research, not medical advice; the current SmPC takes precedence."}}